Abstract
The purpose of this study was to determine whether administration of doxorubicin (DOX) as a continuous infusion or a bolus injection resulted in similar leukemic cell drug concentration in patients with refractory chronic lymphocytic leukemia (CLL). This study was carried out on five patients with refractory CLL, with DOX administered either as a bolus injection (35 mg/m2; CHOP protocol) or as a constant-rate infusion for a period of 96 h (9 mg/m2 per day; VAD protocol). The two types of drug administration were used alternatively with the same patient. Plasma and cellular DOX concentration were determined using high-performance liquid chromatography. Peak plasma DOX levels were higher after the bolus injection than after continuous administration (1509±80 ng/ml vs 11.6±1.8 ng/ml, respectively), whereas the plasma area under the curve (AUC) levels were similar. Maximum DOX cellular concentrations were 8629±2902 ng/109 cells (bolus injection) and 2745±673 ng/109 cells (96 h infusion). The cellular AUC after the bolus injection was 2.85 times greater than that observed after continuous administration. This difference was due to a higher cellular peak level followed by a relatively prolonged retention of the drug, with a loss of only 25% in the first 24 h following. These findings demonstrated that in CLL the cellular DOX exposure can be notably modified by the method of drug administration, with higher drug intracellular concentrations being achieved after bolus administration than with the infusion schedule.
Similar content being viewed by others
References
Andersson B, Beran M, Peterson C, Tribukait B (1982) Significance of cellular pharmacokinetics for the cytotoxic effects of Daunorubicin. Cancer Res 42: 178
Barlogie B, Smith L, Alexanian R (1984) Effective treatment of advanced multiple myeloma refractory to alkalating agents. N Engl J Med 310: 1353
Binet JL, Auquier A, Dighiero G, Chastang C, Piquey H, Goastguen J, Vaugier G, Potron G, Colona P, Oberling F, Thomas M, Tchernia G, Jacquillat C, Boivin P, Lesty C, Duault MT, Monconduit M, Belabbes S, Gremy F (1981) A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer 48: 198
Bonadonna G (1985) Chemotherapy of malignant lymphomas. Sem Oncol 12: 1
Canal P, Sqalli A, De Forni M, Chevreau C, Pujol A, Bugat R, Rocher H, Houstrin J, Houin G (1985) Chronopharmacokinetics of adriamycin in patients with breast cancer. Eur J Clin Pharmacol 40: 287
Coiffier B, Bryon PA, Berger F, Arehimbaud E, French M, Extra JM, Guyotat D, Fiere D, Gentilhomme O, Magaud JP, Blanc M, Peaud PY, Vuvan H, Viala G (1986) Intensive and sequential combination chemotherapy for aggressive malignant lymphomas (protocol LNH-80). J Clin Oncol 4: 147
French Cooperative Group on Chronic Lymphocytic Leukemia (1989) Long-term results of the CHOP regimen in stage C chronic lymphocytic leukemia. Br J Hematol 73: 334
Ganapathi R, Reiter W, Krishan A (1982) Intracellular Adriamycin levels and cytotoxicity in Adriamycin-sensitive and Adriamycin-resistant P388 mouse leukemia cells. J Natl Cancer Inst 68: 1027
Garnick MB, Weiss GR, Steele GD, Israel M, Schade D, Sack MJ, Frei E (1983) Clinical evaluation of long-term continuous-infusion doxorubicin. Cancer Treat Rep 57: 133
Herweijer H, Sonneveld P, Baas F, Nooter F (1990) Expression of mdrl and mdr3 multi-drug resistance genes in acute and chronic leukemias and stimulation of drug accumulation by cyclosporine. J Natl Cancer Inst 82: 1133
Keating MJ, Kantarjiaian H, Talpaz M, Redman J, Koller C, Barlogie B, Velasquez W, Plunkett W, Freireich EJ, McCredie KB (1989) Fludarabine: a new agent with major activity against chronic lymphocytic leukemia. Blood 74: 19
Legha SS, Benjamin RS, Mackay B, Ewer M, Wallace S, Valdivieso M, Rasmussen SL, Blumenschein M, Freireich EJ (1982) Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion. Ann Intern Med 96: 133
McKelvey EM, Gottlieb JA, Wilson HE, Haut A, Talley RW, Stephens R, Lane M, Gamble JF, Jones SE, Grozea PN, Guttermann J, Coltman C, Moon TE (1976) Hydroxyldaunomycin (Adriamycin) combination chemotherapy in malignant lymphomas. Cancer 38: 1484
Miller TP, Grogan TM, Dalton WS, Spier CM, Scheper RJ, Salmon SE (1991) P-glycoprotein expression in malignant lymphoma and reversal of clinical drug resistance with chemotherapy plus high dose verapamil. J Clin Oncol 9: 17
Nguyen-Ngoc T, Vrignaud P, Robert J (1984) Cellular pharmacokinetics of doxorubicin in cultured mouse sarcoma cells originating from autochthonous tumors. Oncology 41: 55
Piro LD, Carrera CJ, Beutler E, Carson DA (1988) 2-chloro-deoxyadenosine: an effective new agent for the treatment of chronic lymphocytic leukemia. Blood 72: 1069
Shustik C, Groulx N, Gros P (1991) Analysis of multidrug resistance (MDR-1) gene expression in chronic lymphocytic leukemia (CLL). Br J Haematol 79: 50
Speth PA, Linssen PC, Boezeman JB, Wessels H, Haanen C (1987a) Cellular and plasma adriamycin concentrations in longterm infusion therapy of leukemia patients. Cancer Chem Pharmacol 20: 305
Speth PA, Linssen PC, Boezeman JB, Wessels H, Haanen C (1987b) Leukemic cell and plasma daunomycin concentrations after bolus injection and 72 h infusion. Cancer Chem Pharmacol 20: 311
Speth PA, Linssen PC, Holdriner RS, Haanen C (1987c) Plasma and cellular Adriamycin concentrations in patients with myeloma treated with ninety-six-hour continuous infusion. Clin Pharmacol Ther 41: 661
Velasquez WS, McLaughlin P, Alexanian R, Barlogie B, Swan F, Caballinas F (1988) Combination of dexamethasone, doxorubicin (Adriamycin) and vincristine (VAD) in chronic lymphocytic leukemia and diffuse small lymphocytic lymphoma. Blood 72: 232a
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Muller, C., Chatelut, E., Gualano, V. et al. Cellular pharmacokinetics of doxorubicin in patients with chronic lymphocytic leukemia: comparison of bolus administration and continuous infusion. Cancer Chemother. Pharmacol. 32, 379–384 (1993). https://doi.org/10.1007/BF00735923
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00735923